ECVAM and pharmaceuticals.
Altern Lab Anim
; 30 Suppl 2: 221-3, 2002 Dec.
Article
in En
| MEDLINE
| ID: mdl-12513680
ABSTRACT
In the pharmaceutical industry, toxicology testing is normally done by preclinical scientists during the Development phase. In the last decade, the implementation of high-throughput screens during the Discovery phase has resulted in an ever-increasing number of lead candidates to be selected for drug development. The low throughput of the conventional safety tests is a bottleneck in the drug-development process. The pharmaceutical industry needs new techniques, down-scaled tests and in vitro alternative test models to determine the absorption, distribution, metabolism, and excretion (ADME) and toxicology profiles of compounds in the late-Discovery phase and/or early in the Development phase. Medium-throughput ADME and toxicity tests will enhance the selection of safer new chemical entities for animals and/or humans. Consequently, this testing strategy will not only reduce the use of resources and the overall development time, but will also result in a substantial decrease in animal use.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drugs, Investigational
/
Toxicity Tests
/
Drug Evaluation, Preclinical
/
Animal Testing Alternatives
Type of study:
Etiology_studies
/
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Altern Lab Anim
Year:
2002
Type:
Article
Affiliation country:
Belgium